Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAMNASDAQ:HALONASDAQ:RGENNASDAQ:RVMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$20.08+1.4%$21.89$13.52▼$35.25$2.02B2.021.96 million shs667,394 shsHALOHalozyme Therapeutics$61.65+1.8%$60.56$37.97▼$66.00$7.61B1.321.43 million shs313,856 shsRGENRepligen$143.76+0.1%$139.66$102.96▼$182.52$8.07B1.27736,142 shs1.33 million shsRVMDRevolution Medicines$40.72-1.8%$37.42$29.17▼$62.40$7.57B1.371.52 million shs1.26 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics+1.43%+8.55%-10.85%-21.62%-7.39%HALOHalozyme Therapeutics+0.13%+5.73%-5.12%+8.16%+57.04%RGENRepligen-0.77%+9.11%+7.66%-17.57%-13.78%RVMDRevolution Medicines+6.96%+13.43%+11.03%+1.34%+15.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBEAMBeam Therapeutics3.047 of 5 stars4.51.00.00.02.52.50.6HALOHalozyme Therapeutics4.0052 of 5 stars1.31.00.04.42.12.54.4RGENRepligen4.8819 of 5 stars4.33.00.04.53.43.31.9RVMDRevolution Medicines3.7725 of 5 stars3.50.00.04.73.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 3.00Buy$49.45146.35% UpsideHALOHalozyme Therapeutics 2.60Moderate Buy$62.892.02% UpsideRGENRepligen 2.57Moderate Buy$176.8222.99% UpsideRVMDRevolution Medicines 3.00Buy$66.6763.74% UpsideCurrent Analyst Ratings BreakdownLatest BEAM, RGEN, RVMD, and HALO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/28/2025RVMDRevolution MedicinesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$67.00 ➝ $67.004/25/2025HALOHalozyme TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.004/21/2025HALOHalozyme TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$55.00 ➝ $58.004/16/2025RGENRepligenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$170.00 ➝ $150.004/8/2025RVMDRevolution MedicinesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$59.00 ➝ $59.004/7/2025BEAMBeam TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.004/1/2025RVMDRevolution MedicinesStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$78.00 ➝ $64.003/28/2025BEAMBeam TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$42.00 ➝ $42.003/18/2025RGENRepligenEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageIn-Line$155.003/12/2025BEAMBeam TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/10/2025BEAMBeam TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$34.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$63.52M31.78N/AN/A$12.04 per share1.67HALOHalozyme Therapeutics$1.02B7.50$4.99 per share12.35$2.95 per share20.90RGENRepligen$634.44M12.72$2.68 per share53.61$35.19 per share4.09RVMDRevolution Medicines$742K10,201.41N/AN/A$11.09 per share3.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$132.53M-$4.58N/AN/AN/A-41.07%-16.22%-10.94%5/6/2025 (Estimated)HALOHalozyme Therapeutics$281.59M$3.4317.979.910.4243.74%157.78%25.34%5/6/2025 (Estimated)RGENRepligen$35.60M-$0.51N/A60.924.54-4.64%4.21%2.94%4/29/2025 (Estimated)RVMDRevolution Medicines-$436.37M-$3.57N/AN/AN/AN/A-33.67%-30.08%5/6/2025 (Estimated)Latest BEAM, RGEN, RVMD, and HALO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025RVMDRevolution Medicines-$1.10N/AN/AN/AN/AN/A5/6/2025Q1 2025BEAMBeam Therapeutics-$1.11N/AN/AN/A$14.69 millionN/A5/6/2025Q1 2025HALOHalozyme Therapeutics$0.98N/AN/AN/A$231.21 millionN/A4/29/2025Q1 2025RGENRepligen$0.35$0.39+$0.04$0.10$163.65 millionN/A2/26/2025Q4 2024RVMDRevolution Medicines-$1.01-$1.12-$0.11-$1.12$0.35 millionN/A2/25/2025Q4 2024BEAMBeam Therapeutics-$1.25-$1.09+$0.16-$1.09$16.47 million$30.00 million2/20/2025Q4 2024RGENRepligen$0.41$0.44+$0.03-$0.60$167.58 million$167.55 million2/18/2025Q4 2024HALOHalozyme Therapeutics$1.17$1.19+$0.02$1.06$285.74 million$298.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam Therapeutics$0.904.48%N/AN/A N/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ARVMDRevolution MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam TherapeuticsN/A5.695.69HALOHalozyme Therapeutics4.147.809.15RGENRepligen0.2610.448.76RVMDRevolution MedicinesN/A14.2414.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%HALOHalozyme Therapeutics97.79%RGENRepligen97.64%RVMDRevolution Medicines94.34%Insider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics4.20%HALOHalozyme Therapeutics2.40%RGENRepligen1.20%RVMDRevolution Medicines8.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics510100.56 million79.33 millionOptionableHALOHalozyme Therapeutics390123.53 million120.20 millionOptionableRGENRepligen2,02056.15 million55.36 millionOptionableRVMDRevolution Medicines250185.91 million154.76 millionOptionableBEAM, RGEN, RVMD, and HALO HeadlinesRecent News About These CompaniesArtia Global Partners LP Raises Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)April 29 at 7:00 AM | marketbeat.comWhy Revolution Medicines, Inc.’s (RVMD) Stock Is Up 5.47%April 29 at 6:39 AM | aaii.comAquatic Capital Management LLC Buys 78,605 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)April 29 at 6:35 AM | marketbeat.comSusquehanna Fundamental Investments LLC Invests $10 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)April 29 at 6:24 AM | marketbeat.comTower Research Capital LLC TRC Has $808,000 Position in Revolution Medicines, Inc. (NASDAQ:RVMD)April 29 at 4:46 AM | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) is Decheng Capital LLC's 8th Largest PositionApril 28 at 7:18 AM | marketbeat.comOxford Asset Management LLP Acquires New Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)April 28 at 7:01 AM | marketbeat.comGhisallo Capital Management LLC Makes New $11.25 Million Investment in Revolution Medicines, Inc. (NASDAQ:RVMD)April 28 at 6:37 AM | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Purchased by Adage Capital Partners GP L.L.C.April 28 at 5:37 AM | marketbeat.com7,306 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Acquired by Syon Capital LLCApril 28 at 5:36 AM | marketbeat.comPrice T Rowe Associates Inc. MD Purchases 552,657 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)April 28 at 5:08 AM | marketbeat.comNatixis Sells 83,624 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)April 28 at 4:35 AM | marketbeat.comInvesco Ltd. Has $5.15 Million Position in Revolution Medicines, Inc. (NASDAQ:RVMD)April 28 at 3:33 AM | marketbeat.comRevolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual MeetingApril 27 at 12:05 PM | globenewswire.comLord Abbett & CO. LLC Has $86.55 Million Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)April 27 at 6:56 AM | marketbeat.comMetLife Investment Management LLC Boosts Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)April 27 at 4:59 AM | marketbeat.comHood River Capital Management LLC Raises Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD)April 25, 2025 | marketbeat.comRock Springs Capital Management LP Grows Position in Revolution Medicines, Inc. (NASDAQ:RVMD)April 23, 2025 | marketbeat.comRaymond James Financial Inc. Takes Position in Revolution Medicines, Inc. (NASDAQ:RVMD)April 23, 2025 | marketbeat.comWells Fargo & Company MN Has $3.86 Million Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)April 23, 2025 | marketbeat.comRevolution Medicines, Inc. (NASDAQ:RVMD) Shares Bought by Barclays PLCApril 22, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBig Blue's Big Shift: IBM's Turnaround Bet on Cloud and AIBy Jeffrey Neal Johnson | April 7, 2025View Big Blue's Big Shift: IBM's Turnaround Bet on Cloud and AIRetail Data Shows Urgency in Auto Parts: These 3 Stocks Could WinBy Gabriel Osorio-Mazilli | April 22, 2025View Retail Data Shows Urgency in Auto Parts: These 3 Stocks Could WinBEAM, RGEN, RVMD, and HALO Company DescriptionsBeam Therapeutics NASDAQ:BEAM$20.08 +0.28 (+1.39%) As of 02:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Halozyme Therapeutics NASDAQ:HALO$61.64 +1.08 (+1.77%) As of 02:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Repligen NASDAQ:RGEN$143.76 +0.13 (+0.09%) As of 02:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.Revolution Medicines NASDAQ:RVMD$40.72 -0.76 (-1.82%) As of 02:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
